🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › Florida › Orlando

Diffuse Large B-Cell Lymphoma clinical trials in Orlando, FL

5 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

RecruitingPhase 2/3
  • Clermont Oncology Center ( Site 0174), Clermont · 24 mi away
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05139017

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

RecruitingPhase 3
  • Orlando Health Cancer Institute ( Site 0169), Ocoee · 10 mi away
  • Clermont Oncology Center ( Site 0182), Clermont · 24 mi away
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

RecruitingPhase 2
  • Orlando Health Cancer Institute, Orlando
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06806033

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

RecruitingPhase 2
  • Advent Health Cancer Institute, Orlando
  • Orlando Health Cancer Institute, Orlando
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

RecruitingPhase 3
  • AdventHealth, Orlando
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558

Diffuse Large B-Cell Lymphoma trials in other cities

Other studies in Orlando

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.